Vydura: Uses, Dosage & Side Effects
A CGRP receptor antagonist (gepant) for both acute treatment and prevention of migraine in adults
Vydura (rimegepant) is a prescription oral medication belonging to the gepant class of calcitonin gene-related peptide (CGRP) receptor antagonists. It is uniquely approved for both the acute treatment of migraine attacks and the preventive treatment of episodic migraine in adults. Vydura is taken as a 75 mg orally disintegrating tablet that dissolves on the tongue without the need for water. For acute treatment, one tablet is taken as needed (maximum once daily); for prevention, one tablet is taken every other day. Clinical trials have demonstrated that Vydura provides meaningful relief during active migraine attacks while also significantly reducing the frequency of future migraine days when used preventively, making it the first oral CGRP-targeting therapy with this dual indication.
Quick Facts: Vydura
Key Takeaways
- Vydura (rimegepant) is the first oral CGRP receptor antagonist approved for both acute treatment of migraine attacks and preventive treatment to reduce migraine frequency in adults.
- The 75 mg orally disintegrating tablet dissolves on the tongue without water, making it convenient for use during a migraine attack when nausea may make swallowing tablets difficult.
- For acute treatment, take one tablet as needed (max once daily); for prevention, take one tablet every other day. The maximum dose is one tablet per day regardless of indication.
- Vydura has a very favorable side effect profile: nausea is the only common side effect, and serious allergic reactions are uncommon but can occur days after administration.
- Important drug interactions exist with strong CYP3A4 inhibitors (itraconazole, clarithromycin) and inducers (rifampicin, phenobarbital, St. John’s Wort), which should be avoided during treatment.
What Is Vydura and What Is It Used For?
Vydura contains the active substance rimegepant, a small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. Unlike monoclonal antibody CGRP therapies that target the CGRP ligand itself, rimegepant directly blocks the CGRP receptor, preventing CGRP from binding to and activating it. This distinction places Vydura in the gepant class of medications, a group of oral small-molecule CGRP receptor antagonists that have transformed migraine treatment by offering targeted therapy in a convenient oral formulation.
CGRP is a 37-amino acid neuropeptide that plays a central role in migraine pathophysiology. It is abundantly expressed in the trigeminal sensory neurons, the trigeminal ganglion, and the perivascular nerve fibers surrounding cerebral and meningeal blood vessels. During a migraine attack, trigeminal nerve activation leads to a massive release of CGRP into the trigeminovascular system. This surge of CGRP triggers a cascade of pathological events: dilation of intracranial and meningeal blood vessels, release of inflammatory mediators in the meninges (neurogenic inflammation), sensitization of trigeminal pain-processing neurons, and amplification of pain signals transmitted to higher brain centers. Elevated CGRP levels have been consistently measured in the jugular venous blood and saliva of patients during acute migraine attacks, and intravenous infusion of CGRP reliably provokes migraine-like headaches in susceptible individuals.
Rimegepant binds with high affinity to the human CGRP receptor, which is a heterodimeric complex composed of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). By occupying the receptor binding site, rimegepant competitively blocks CGRP from activating the receptor, thereby inhibiting the downstream intracellular signaling that leads to vasodilation, neurogenic inflammation, and central sensitization. This mechanism provides two distinct clinical benefits: it can abort an ongoing migraine attack by rapidly reducing CGRP-mediated signaling in the trigeminovascular system, and it can prevent future migraine attacks when taken regularly by maintaining sustained CGRP receptor blockade.
Vydura is approved for two indications in adults:
- Acute treatment of migraine: Vydura can be taken during an active migraine attack to relieve headache pain and associated symptoms such as nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). In the pivotal phase III trial (Study 301), a single 75 mg dose of rimegepant demonstrated statistically significant superiority over placebo for both co-primary endpoints: pain freedom at 2 hours (19.6% vs 12.0%, p < 0.001) and freedom from the most bothersome symptom at 2 hours (37.6% vs 25.2%, p < 0.001). Benefits were sustained through 48 hours post-dose.
- Preventive treatment of migraine: When taken every other day, Vydura significantly reduces the number of monthly migraine days. In the phase 2/3 prevention trial, rimegepant 75 mg every other day reduced the mean number of monthly migraine days by 4.3 days from baseline compared with 3.5 days for placebo (treatment difference of −0.8 days, p = 0.0099) over the 12-week double-blind treatment period. The proportion of patients achieving a 50% or greater reduction in monthly migraine days was also significantly higher with rimegepant (49.1%) compared with placebo (40.7%).
This dual indication makes Vydura uniquely positioned in the migraine treatment landscape. While injectable CGRP monoclonal antibodies (such as erenumab, fremanezumab, and galcanezumab) are highly effective for migraine prevention, they are not approved for acute treatment. Conversely, traditional acute migraine treatments like triptans are effective for aborting attacks but are not used preventively. Vydura bridges this gap, offering patients and clinicians a single oral therapy that can address both the acute and preventive aspects of migraine management.
Vydura was first approved by the European Medicines Agency (EMA) in April 2022 under the brand name Vydura. In the United States, the same active substance (rimegepant) was approved by the FDA in February 2020 for acute treatment and in May 2021 for preventive treatment, marketed under the brand name Nurtec ODT. It is now available in numerous countries worldwide and has become an important addition to the armamentarium of CGRP-targeted therapies for migraine.
Vydura is the first oral CGRP-targeting medication approved for both acute treatment and prevention of migraine. This means patients can use a single medication to treat attacks when they occur and to reduce the frequency of future attacks when taken every other day. This dual-action approach simplifies treatment regimens and may improve medication adherence for patients with frequent migraines who need both acute and preventive therapy.
What Should You Know Before Taking Vydura?
Contraindications
Vydura must not be taken if you are allergic (hypersensitive) to rimegepant or to any of the other ingredients in the medication, which include gelatin, mannitol, mint flavoring agent, and sucralose. Hypersensitivity to any component of the formulation is an absolute contraindication to the use of this medication. If you have previously experienced an allergic reaction to rimegepant, you should not take Vydura again under any circumstances.
Additionally, Vydura should not be co-administered with strong CYP3A4 inhibitors such as itraconazole, clarithromycin, or ritonavir, as these medications significantly increase rimegepant plasma concentrations and can lead to increased risk of adverse effects. Strong CYP3A4 inducers such as rifampicin, phenobarbital, and efavirenz should also be avoided, as they significantly reduce rimegepant plasma concentrations and may render the medication ineffective.
Warnings and Precautions
Before starting Vydura, it is essential to discuss your complete medical history with your healthcare provider. Special caution is required in the following situations:
- Severe hepatic impairment: Patients with severe liver problems (Child-Pugh class C) should avoid using Vydura. Rimegepant is primarily metabolized by the liver through the CYP3A4 enzyme pathway, and severe hepatic impairment can lead to significantly elevated drug levels in the blood, increasing the risk of adverse effects. No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A), but patients with moderate hepatic impairment (Child-Pugh class B) should use Vydura with caution and under close medical supervision.
- Renal impairment: Patients with impaired kidney function or those on dialysis should discuss Vydura use with their doctor. While rimegepant is primarily eliminated through hepatic metabolism rather than renal excretion, limited data are available for patients with severe renal impairment or end-stage renal disease requiring dialysis. Caution is advised in these patient populations.
- Allergic reactions: Hypersensitivity reactions, including dyspnea (difficulty breathing) and severe rash, have been reported with rimegepant use. Importantly, these allergic reactions can manifest several days after taking the medication, making delayed-onset hypersensitivity a particular concern. If you experience any signs of an allergic reaction — including difficulty breathing, hives, swelling of the face, lips, tongue, or throat, or severe skin rash — stop taking Vydura immediately and seek medical attention.
Allergic reactions to Vydura can occur several days after taking the medication. If you develop breathing difficulties or severe rash at any time after taking Vydura, stop taking the medication and contact your doctor immediately, even if several days have passed since your last dose.
Children and Adolescents
Vydura should not be given to children and adolescents under 18 years of age. The safety and efficacy of rimegepant have not been established in this age group. Clinical trials for Vydura were conducted exclusively in adult populations (18 years and older), and there are insufficient data to support its use in pediatric patients. If a child or adolescent suffers from migraine, alternative treatments should be discussed with a healthcare provider experienced in pediatric headache management.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using Vydura. The use of Vydura during pregnancy should be avoided as a precaution, because the effects of rimegepant on pregnant women and the developing fetus have not been adequately studied in clinical trials. Animal reproductive toxicity studies did not reveal direct harmful effects on pregnancy, embryonic or fetal development, parturition, or postnatal development. However, these animal data cannot be directly extrapolated to humans, and the potential risk for humans remains unknown.
If you are breastfeeding or planning to breastfeed, discuss with your doctor whether to use Vydura. It is not known whether rimegepant is excreted in human breast milk in clinically significant amounts. A decision must be made whether to discontinue breastfeeding or to discontinue Vydura therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Your healthcare provider can help you weigh these considerations.
Driving and Operating Machinery
Vydura is not expected to affect your ability to drive or operate machinery. In clinical trials, rimegepant did not demonstrate any significant effects on psychomotor function, attention, or reaction time. However, migraine itself can impair your ability to concentrate and react, so you should assess your own condition before driving or operating heavy machinery during a migraine attack, regardless of whether you have taken Vydura.
How Does Vydura Interact with Other Drugs?
Rimegepant is primarily metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme, with minor contributions from CYP2C9. It is also a substrate of the P-glycoprotein (P-gp) efflux transporter. This metabolic profile means that medications which significantly inhibit or induce CYP3A4, or that inhibit P-gp, can substantially alter rimegepant blood levels, either increasing the risk of side effects (with inhibitors) or reducing efficacy (with inducers). Understanding these interactions is critical for the safe and effective use of Vydura.
Major Interactions — Medications to Avoid
The following medications should not be taken concomitantly with Vydura because they can cause clinically significant changes in rimegepant plasma concentrations:
| Medication | Type | Used For | Effect on Vydura |
|---|---|---|---|
| Itraconazole | Strong CYP3A4 inhibitor | Fungal infections | Significantly increases rimegepant levels |
| Clarithromycin | Strong CYP3A4 inhibitor | Bacterial infections | Significantly increases rimegepant levels |
| Ritonavir | Strong CYP3A4 inhibitor/inducer | HIV infections | Significantly alters rimegepant levels |
| Efavirenz | Strong CYP3A4 inducer | HIV infections | Significantly reduces rimegepant levels |
| Rifampicin | Strong CYP3A4 inducer | Tuberculosis | Significantly reduces rimegepant levels |
| Phenobarbital | Strong CYP3A4 inducer | Epilepsy | Significantly reduces rimegepant levels |
| St. John’s Wort | CYP3A4 inducer | Mild depression, anxiety | Reduces rimegepant levels |
| Bosentan | Moderate CYP3A4 inducer | Pulmonary hypertension | Reduces rimegepant levels |
| Modafinil | Moderate CYP3A4 inducer | Narcolepsy | Reduces rimegepant levels |
Moderate Interactions — Dosing Adjustment Required
When taking Vydura together with moderate CYP3A4 inhibitors or P-gp inhibitors, the dosing frequency must be restricted to no more than once every 48 hours. These medications moderately increase rimegepant plasma concentrations, which can be managed by extending the dosing interval:
| Medication | Type | Used For | Dosing Adjustment |
|---|---|---|---|
| Fluconazole | Moderate CYP3A4 inhibitor | Fungal infections | Max 1 dose every 48 hours |
| Erythromycin | Moderate CYP3A4 inhibitor | Bacterial infections | Max 1 dose every 48 hours |
| Diltiazem | Moderate CYP3A4 inhibitor | Heart rhythm disorders, angina, hypertension | Max 1 dose every 48 hours |
| Verapamil | Moderate CYP3A4 inhibitor | Heart rhythm disorders, angina, hypertension | Max 1 dose every 48 hours |
| Quinidine | P-gp inhibitor | Heart rhythm disorders | Max 1 dose every 48 hours |
| Cyclosporine | P-gp inhibitor | Organ transplant rejection prevention | Max 1 dose every 48 hours |
Tell your doctor or pharmacist about all medications you are taking, have recently taken, or might take, including over-the-counter medicines, herbal supplements, and vitamins. Drug interactions can change how Vydura works or increase your risk of side effects. Your doctor can determine the safest treatment plan for you.
What Is the Correct Dosage of Vydura?
Always take Vydura exactly as your doctor or pharmacist has told you. Do not change your dose or stop taking Vydura without first consulting your healthcare provider. The orally disintegrating tablet formulation is designed for convenience and rapid onset, dissolving directly on the tongue without the need for water, which is particularly beneficial during a migraine attack when nausea may make swallowing conventional tablets difficult.
Adults
Preventive Treatment of Migraine
The recommended dose is one oral lyophilisate (75 mg rimegepant) every other day (every 48 hours). Take the tablet at approximately the same time on dosing days for optimal steady-state drug levels. Consistency in dosing is important for maximizing the preventive benefit. Your doctor will typically evaluate the effectiveness of preventive treatment after 3 months.
Acute Treatment of a Migraine Attack
The recommended dose is one oral lyophilisate (75 mg rimegepant) as needed when a migraine attack begins. Do not take more than one tablet in any 24-hour period. If you are already taking Vydura for prevention (every other day) and experience a migraine attack, you may take one tablet for acute treatment, but the total maximum dose remains one tablet per day.
How to Take Vydura
Vydura oral lyophilisate is designed for sublingual or supralingual administration. Follow these steps carefully:
- Ensure your hands are dry before opening the packaging. Moisture can damage the delicate lyophilisate tablet.
- Peel back the foil from one blister and carefully remove the tablet. Do not push the tablet through the foil, as this can break the fragile lyophilisate.
- Place the tablet immediately on or under the tongue. The tablet will dissolve within seconds without the need for water or any other liquid.
- Do not store the tablet outside the blister pack for future use. Once removed from the blister, the tablet should be taken immediately.
The tablet can be taken with or without food. Taking it with or without water does not affect its efficacy, although no water is required for the tablet to dissolve.
Children and Adolescents
Vydura is not recommended for use in children and adolescents under 18 years of age due to insufficient safety and efficacy data in this population. Pediatric migraine should be managed by a specialist experienced in treating headache in children.
Elderly Patients
No dose adjustment is required for elderly patients. Clinical trial data included patients over 65 years of age, and no differences in safety or efficacy were observed compared with younger adults. However, elderly patients are more likely to have hepatic or renal impairment and to take multiple medications, so the potential for drug interactions should be carefully assessed.
Missed Dose
If you are taking Vydura for migraine prevention and miss a dose, simply take the next dose at your regular scheduled time. Do not take a double dose to make up for the forgotten one. Doubling the dose will not improve the preventive effect and may increase the risk of side effects.
Overdose
If you have taken more Vydura than prescribed, contact your doctor, pharmacist, or go to a hospital emergency department immediately. Bring the medication package and this information with you. In clinical studies, single doses of up to 1,500 mg and multiple doses of up to 600 mg per day for 7 days were administered without clinically significant safety concerns beyond the known side effect profile. However, any suspected overdose should be evaluated by a healthcare professional.
Prevention: 75 mg every other day. Acute treatment: 75 mg as needed (max once daily). Maximum in any scenario: one 75 mg tablet per day. The tablet dissolves on the tongue — no water needed. Can be taken with or without food.
What Are the Side Effects of Vydura?
Like all medicines, Vydura can cause side effects, although not everybody gets them. The overall safety profile of rimegepant is very favorable compared with many other migraine medications. Clinical trials involving thousands of patients have demonstrated that Vydura is generally well tolerated, with most adverse events being mild and transient.
However, it is important to be aware of the potential for delayed hypersensitivity reactions. Unlike most immediate allergic reactions that occur within minutes to hours of exposure, allergic reactions to Vydura can manifest several days after the dose was taken. This delayed presentation makes it critical to remain vigilant for symptoms of allergic reactions even days after taking the medication.
If you develop signs of a serious allergic reaction such as severe skin rash, difficulty breathing, swelling of the face, lips, tongue, or throat, stop taking Vydura immediately and seek emergency medical care. These reactions can occur several days after taking the medication.
Common Side Effects
May affect up to 1 in 10 people
- Nausea
Uncommon Side Effects
May affect up to 1 in 100 people
- Hypersensitivity reactions (allergic reactions)
- Severe rash
- Dyspnea (difficulty breathing)
Understanding the Side Effect Profile
The remarkably clean side effect profile of Vydura is one of its most significant clinical advantages. In the pivotal acute treatment trial (Study 301), the incidence of nausea was 1.8% with rimegepant 75 mg compared with 1.1% with placebo, a modest difference that underscores the good tolerability of the medication. In the prevention trial, nausea was reported by approximately 2.7% of patients on rimegepant compared with 1.6% on placebo over the 12-week treatment period.
Importantly, unlike triptans (which can cause chest tightness, tingling, drowsiness, and are contraindicated in patients with cardiovascular disease), Vydura does not cause vasoconstriction and is not associated with cardiovascular adverse effects. This makes it a valuable option for patients who cannot use triptans due to cardiovascular risk factors, uncontrolled hypertension, or a history of stroke or heart attack.
The medication does not appear to cause medication-overuse headache (MOH) when used frequently for acute treatment, which is a significant concern with triptans and analgesics. In long-term open-label extension studies lasting up to 52 weeks, no new safety signals emerged, and the incidence of adverse events remained consistent with the controlled trial data, supporting the long-term tolerability of rimegepant.
Hepatotoxicity (liver damage) has not been identified as a concern with rimegepant at approved doses, in contrast to earlier gepants (such as the discontinued olcegepant and telcagepant), which showed hepatotoxicity signals in clinical development. Liver function tests remained stable in patients treated with rimegepant across all clinical trials.
Reporting Side Effects
It is important to report any suspected side effects to your healthcare provider. Reporting side effects after a medication is approved helps ongoing monitoring of the medication’s benefit-risk profile. You can also report suspected adverse reactions directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA’s EudraVigilance system in the European Union).
How Should You Store Vydura?
Proper storage of Vydura is essential to maintain the integrity and effectiveness of the orally disintegrating tablet. The lyophilisate formulation is particularly sensitive to moisture, which is why specific storage instructions must be carefully followed.
- Temperature: Store at or below 30°C (86°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
- Packaging: Keep the tablets in the original blister pack until ready for use. The foil blister provides essential moisture protection for the lyophilisate tablet. Do not transfer tablets to pill organizers or other containers.
- Moisture protection: The orally disintegrating tablet is moisture-sensitive. Do not store an unwrapped tablet for later use. Once the foil is peeled back, take the tablet immediately.
- Expiration date: Do not use Vydura after the expiration date (EXP) printed on the carton and blister pack. The expiration date refers to the last day of that month.
- Children: Keep this medicine out of the sight and reach of children.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
What Does Vydura Contain?
Active Ingredient
Each oral lyophilisate contains 75 mg of rimegepant (as rimegepant sulfate). Rimegepant sulfate is the salt form of the active substance that provides optimal stability and dissolution characteristics for the lyophilisate formulation. The 75 mg strength refers to the amount of rimegepant base, not the total weight of the salt form.
Inactive Ingredients (Excipients)
The following excipients are present in the Vydura oral lyophilisate formulation:
- Gelatin: Provides the structural matrix for the lyophilisate tablet, enabling rapid disintegration on the tongue.
- Mannitol: A sugar alcohol that serves as a bulking agent and contributes to the pleasant taste and mouthfeel of the dissolving tablet.
- Mint flavoring agent: Provides a pleasant mint taste that enhances patient acceptability and masks any medicinal taste.
- Sucralose: An artificial sweetener that contributes to the palatable taste of the formulation.
Appearance and Pack Sizes
Vydura 75 mg oral lyophilisate tablets are white to off-white, round tablets. They are available in the following pack sizes:
- 2 × 1 tablets in perforated unit-dose blisters in a wallet pack
- 8 × 1 tablets in perforated unit-dose blisters
- 16 × 1 tablets in perforated unit-dose blisters
Not all pack sizes may be marketed in every country. The wallet pack containing 2 tablets is particularly convenient for carrying in a purse or pocket for acute treatment of unexpected migraine attacks.
Marketing Authorization Holder
The marketing authorization holder for Vydura in the European Union is Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium. The medication is manufactured at facilities in Ireland (HiTech Health Limited, Millmount Healthcare Limited, and Pfizer Ireland Pharmaceuticals).
Frequently Asked Questions About Vydura
Yes, Vydura (rimegepant) is uniquely approved for both indications. For acute treatment, take one 75 mg tablet as needed when a migraine begins (maximum once daily). For prevention, take one 75 mg tablet every other day. If you are using Vydura for prevention and experience a breakthrough migraine, you may take an additional dose for acute treatment, but the maximum remains one tablet per day. This dual-action capability makes Vydura the first oral CGRP-targeting therapy approved for both purposes.
In clinical trials, Vydura demonstrated significant pain relief as early as 60 minutes after dosing, with pain freedom achieved by approximately 1 in 5 patients at 2 hours. The orally disintegrating tablet is absorbed through the oral mucosa and gastrointestinal tract, reaching peak blood levels in approximately 1.5 hours. Many patients notice meaningful improvement in headache pain and associated symptoms (such as light and sound sensitivity) within the first 1–2 hours. Benefits continue through 48 hours after the dose.
Vydura works through a fundamentally different mechanism than triptans. While triptans constrict blood vessels (which is why they are contraindicated in patients with coronary artery disease, stroke, or uncontrolled hypertension), Vydura blocks the CGRP receptor without causing vasoconstriction. This makes Vydura an important alternative for migraine patients who cannot use triptans due to cardiovascular risk factors. However, Vydura has not been extensively studied in patients with significant cardiovascular disease, so consult your doctor about the most appropriate treatment for your individual situation.
Based on available clinical trial data, rimegepant does not appear to cause medication-overuse headache (MOH), which is a significant advantage over triptans and simple analgesics. In long-term studies, patients who used rimegepant frequently for acute treatment did not show an increase in headache frequency or worsening of migraine patterns characteristic of MOH. However, as with any acute migraine medication, it is advisable to follow your doctor’s guidance on appropriate frequency of use.
Vydura and Nurtec ODT contain the same active ingredient (rimegepant 75 mg) and are essentially the same medication marketed under different brand names in different regions. Vydura is the brand name used in the European Union and several other countries, while Nurtec ODT is the brand name used in the United States. Both are manufactured by Pfizer (which acquired Biohaven Pharmaceuticals, the original developer). The formulation, dosage, and approved indications are the same.
Vydura can generally be used alongside many other migraine treatments. In clinical practice, it is commonly combined with preventive medications such as beta-blockers, anticonvulsants (topiramate, valproate), or antidepressants (amitriptyline) without significant interactions. However, there are no specific studies on combining Vydura with injectable CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab), and this combination should only be considered under specialist supervision. Always inform your doctor about all medications you are taking, especially those listed in the drug interactions section.
References
- European Medicines Agency (EMA). Vydura (rimegepant) — Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/vydura
- U.S. Food and Drug Administration (FDA). Nurtec ODT (rimegepant) — Prescribing Information. Revised 2024. Available at: accessdata.fda.gov
- Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745. doi:10.1016/S0140-6736(19)31606-X
- Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60. doi:10.1016/S0140-6736(20)32544-7
- American Headache Society (AHS). Consensus Statement: The Integration of New Migraine Treatments into Clinical Practice. Headache. 2023;63(1):1–18.
- Ashina M, Buse DC, Ashina S, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–1518. doi:10.1016/S0140-6736(20)32342-4
- European Headache Federation (EHF). Guideline on the use of monoclonal antibodies and gepants acting on the calcitonin gene-related peptide pathway for migraine prevention and treatment. J Headache Pain. 2024;25(1):58.
- World Health Organization (WHO). Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.
- British National Formulary (BNF). Rimegepant. National Institute for Health and Care Excellence (NICE). Updated 2025.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, composed of licensed healthcare professionals with expertise in neurology, clinical pharmacology, and evidence-based medicine.
Medical Content Team
Board-certified neurologists and clinical pharmacologists with specialized training in headache medicine and CGRP-targeted therapies.
Medical Review Board
Independent panel of medical experts who verify clinical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, AHS, EHF).
Evidence Standards
All medical claims are supported by Level 1A evidence from systematic reviews, randomized controlled trials, and international clinical guidelines. GRADE evidence framework applied.
Editorial Independence
iMedic maintains complete editorial independence with no pharmaceutical company funding, sponsorship, or advertising. All content decisions are made solely by the medical editorial team.
Last medically reviewed: | Published: